MCK logo

McKesson Corporation Stock Price

NYSE:MCK Community·US$99.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 115 Fair Values set on narratives written by author

MCK Share Price Performance

US$838.75
132.75 (18.80%)
US$980.80
Fair Value
US$838.75
132.75 (18.80%)
14.5% undervalued intrinsic discount
US$980.80
Fair Value
Price US$838.75
AnalystConsensusTarget US$980.80

MCK Community Narratives

·
Fair Value US$980.8 14.5% undervalued intrinsic discount

Analysts Boost McKesson Outlook Amid Strong Growth Guidance and Recent Valuation Adjustments

0users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
US$980.8
14.5% undervalued intrinsic discount
Revenue
6.91% p.a.
Profit Margin
1.24%
Future PE
18.19x
Price in 2029
US$1.21k

Trending Discussion

No trending discussion available.

Updated Narratives

MCK logo

MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal

Fair Value: US$980.8 14.5% undervalued intrinsic discount
57 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards

McKesson Corporation Key Details

US$411.0b

Revenue

US$396.1b

Cost of Revenue

US$14.9b

Gross Profit

US$10.3b

Other Expenses

US$4.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
39.39
3.63%
1.12%
-742.5%
View Full Analysis

About MCK

Founded
1833
Employees
42300
CEO
Brian Tyler
WebsiteView website
www.mckesson.com

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Recent MCK News & Updates

Seeking Alpha Aug 08

McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade)

Summary McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company's top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers. While the valuation isn't overly attractive, management is executing well, and I'm upgrading shares to a hold rating today. Read the full article on Seeking Alpha
Narrative Update Aug 06

MCK: Biosimilar Co Manufacturing Optionality Will Drive Future Defensive Haven Appeal

McKesson's analyst fair value estimate has been raised from $941.40 to $980.80 as analysts factor in higher Street price targets and updated models that reference recent quarterly results, peer multiple moves, and shifting assumptions on long term P/E and profitability. Analyst Commentary Recent Street research on McKesson points to a mixed but generally constructive view on valuation and execution, with several firms revising price targets following quarterly updates and changes in sector assumptions.

Recent updates

No updates